Based on Miltenyi Biotec's longstanding expertise and experience in the field of T cell engineering, we provide a tested workflow for CAR T cell research.
Our solutions enable you to isolate donor T cells and to achieve efficient T cell activation, gene transfer, and expansion. Furthermore, we offer instruments, reagents, and software for functional characterization of rare CAR T cell populations.
Take advantage of our experience and expertise in CAR T cell research and clinical manufacturing and benefit from our standardized, translational workflow. Start with our tailored solutions for research and development of your engineered T cells. Once your small-scale workflow has been successfully developed, you can transfer your process to the CliniMACS Prodigy® Platform using the corresponding MACS® GMP Portfolio for larger scale production. Seamless, quick, and easy from bench to bedside.
Watch our recorded webinars to learn about tips and tricks that get your CAR T cell research moving.
Following on from our renowned webinar “Improve your CAR T cell research”, this webinar will cover our latest product solutions and strategies to efficiently move your CAR T cell research forward. Tune in and learn how to: Isolate fully functional T cells directly from whole blood and blood products , boost lentiviral T cell transduction efficiency, easily activate and expand your T cells without hassle and advance your IPC and QC with our latest flow analysis solutions.
Explore the power of ultra high content and 3D imaging for the identification and characterization of new CAR T cell targets. Learn more about the visualization of hundreds of markers from one single sample using a new fully automated imaging process and see how light sheet microscopy provides new insights for three-dimensional visualization and characterization of tumor antigens in large tissue samples.
Starting your workflow with a well-defined, enriched T cell population is key to obtain robust, standardized, and reproducible results. Depending on the starting material, PBMCs or blood products, you choose either standard MACS® MicroBeads and Isolation Kits or the innovative StraightFrom® Technology. But independent of the approach, the basis is always the proven and most cited MACS MicroBead Technology. In addition, to enable a seamless transition of your research workflow to the CliniMACS Prodigy® Platform, MACS MicroBeads are available in MACS GMP Quality.
Positive selection enables straightforward isolation of CD4+ and CD8+ T cells from PBMCs using MACS MicroBeads and MicroBead Kits.
Simultaneous enrichment of CD4+ and CD8+ T cells makes for a homogeneous starting cell population. T cell enrichment minimizes donor variability, improves transduction efficiency, and avoids vector consumption by unwanted cells, allowing for robust, standardized, and reproducible results.
If subsequent magnetic sorting steps are required, untouched cell isolation using MACS T Cell Isolation Kits allows for isolation of unlabeled target cells via depletion of non-target cells.
Increase throughput and productivity with StraightFrom® Technology for T cell isolation directly from whole blood and blood products (buffy coat, LRSC, and Leukopak®) without density gradient centrifugation or RBC lysis.
Using the innovative StraightFrom MicroBead Technology facilitates the omission of the density-gradient centrifugation step for PBMC generation, saving processing time and reducing user variability.
A comparison of standard MACS MicroBeads and StraightFrom MicroBead Kits reveal that regardless of the isolation approach, magnetic cell separation using MACS Technology ensures preservation of T cell functionality enabling full downstream compatibility for CAR T cell generation. This novel approach is automatable using the MultiMACS™ Cell24 Separator Plus to further increase throughput and productivity.
The MACSprep™ CD19 CAR MicroBead Kit was developed for fast and convenient CAR T cell isolation from fresh blood samples.
Low frequency CAR T cells were enriched directly from whole blood samples without density gradient centrifugation using the MACSprep CD19 CAR MicroBead Kit for further flow cytometric, functional, and molecular analysis.
Physiological T cell activation is vital to start the proliferation and expansion process and facilitate an efficient T cell transduction. Optimal T cell expansion relies on the synergistic effect of T Cell TransAct™, TexMACS™ Medium, and MACS Cytokines.
T Cell TransAct enables biologically appropriate, robust activation of resting T cells via humanized CD3 and CD28 antagonists conjugated to a polymeric nanomatrix. T cell activation was verified by expression of T Cell activation marker CD25 and CD69.
Moreover, with its unique features, T Cell TransAct is superior to conventional methods and has been developed to be used in an automated closed system.
T cell expansion rates after activation with T Cell TransAct and culture in serum-free TexMACS Medium were compared with stimulation using a bead-based competitor product and RPMI medium. Analyses revealed identical expansion rates, even under serum-free conditions. Especially in clinical manufacturing, a serum-free T cell expansion is advantageous as human serum can be the limiting factor. Both media were supplemented with Human IL-2 IS, premium grade (50 U/mL).
Watch the video and learn how T Cell TransAct can optimize your T cell research.
Our application protocol describes a complete workflow for engineering CAR T cells for research. Including T cell isolation, activation, gene-transfer of the CAR construct, CAR T cell expansion, as well as phenotyping and functional analysis.
Transgene expression depends on gene transfer efficiency. However, viral transduction of suspension cells with retroviral vectors is often inefficient and requires the use of transduction enhancers.
Using the synthetic, non-toxic soluble Vectofusin®-1 with a simple and easy-to-follow protocol enhances the transduction efficiency of viral vectors.
Applying Vectofusin®-1 directly to the cell culture medium increases the transduction efficiency and thus reduces the amount and cost of viral vector needed per experiment. Applicable for both, static and spinoculation protocols.
As the success of CAR T cell therapies has been associated with the phenotype, activation status, and functional profiling of CAR T cells, the reliable and standardized characterization of those parameter is crucial.
Our CAR T cell analytics portfolio provides all you need for reliable, reproducible, and standardized analysis. Use our high-quality reagents, instruments, and software to streamline your CAR T cell analysis – from basic research and discovery to IPC/QC in clinical manufacturing.
Tune into the recordings of Miltenyi Biotec´s Cell Therapy Analytics Day 2021 to discover lessons learned, master best practices, and overcome regulatory hurdles in order to simplify your cell manufacturing analytics. Or watch our three-part webinar series on Standardizing flow cytometry assays in cell manufacturing to learn about automated tools for CAR T cell analysis.
Our optimized and validated panels of fluorochrome-conjugated REAfinity™ Recombinant Antibodies and CAR Detection Reagents help to streamline the phenotypic characterization of CAR T cells. For maximum reproducibility and standardization of in-process-control (IPC) and quality control (QC) for your clinical manufacturing process, combine the StainExpress™ Dried Antibody Cocktails with the MACSQuant® Analyzer and the Express Modes.
Benefit from Miltenyi Biotec Tested Panels (MBTP) including antibody panels, step-by-step protocols, and gating strategies to accelerate your CAR T cell flow analysis.
Express Modes are a unique add-on for the MACSQuantify™ Software, developed to simplify flow cytometric analysis and maximize reproducibility of data analysis. They automate the measurement and analysis of flow experiments via predefined experiment settings as well as acquisition and automated analysis.
Our ready-to-use biotinylated CAR Detection Reagents have been developed for the detection of T cells that are engineered to express a specific CAR on the cell surface, e.g., CD19 CAR or CD22 CAR.
CD19 CAR Detection Reagent (Biotin) detects CD19 CAR T cells via recognition of the CD19 CAR molecule, here shown on day 12 after expansion.
We offer flow cytometry solutions to improve the quality of potency assay results. They can, for example, be used for high-throughput and automated in vitro potency assays to assess CAR T cells’ antigen-specific killing, T cell phenotype, intracellular cytokine detection, as well as effector cytokine secretion.
Conventional intracellular staining procedure using REAfinity Antibodies and CAR Detection Reagents in combination with the Inside Stain Kit allow for successful detection of CAR T cells that secrete effector cytokines such as IFN-γ, TNF-α, or IL-2.
The accurate quantification of cytokines facilitates detailed examination of newly engineered CAR T cells. MACSPlex Cytokine Kits were designed for easy quantification of secreted cytokines in cell culture supernatant, making it easy to assess CAR T cell functionality.
Phenotyping, cytokine profiling, and cytotoxicity testing: multiple readouts within one single co-culture assay.
Ultra high content imaging allows for CAR T cell target discovery, in-depth tumor infiltration analysis, as well as assessment of preclinical CAR T cell target safety and CAR T cell biodistribution.
A new publication in Nature Communications reveals target candidates for CAR T cell–based immunotherapy of pancreatic adenocarcinoma.
Explore the scientific publication.
Daniel Schaefer, Stefan Tomiuk, Laura N. Küster, Wa’el Al Rawashdeh, Janina Henze, German Tischler-Höhle, David J. Agorku, Janina Brauner, Cathrin Linnartz, Dominik Lock, Andrew Kaiser, Christoph Herbel, Dominik Eckardt, Melina Lamorte, Dorothee Lenhard, Julia Schüler, Philipp Ströbel, Jeannine Missbach-Guentner, Diana Pinkert-Leetsch, Frauke Alves, Andreas Bosio, and Olaf Hardt